Informatie:
Fout:
ID
31752
Beschrijving
A Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple Myeloma; ODM derived from: https://clinicaltrials.gov/show/NCT00912899
Link
https://clinicaltrials.gov/show/NCT00912899
Trefwoorden
Versies (1)
- 25-09-18 25-09-18 -
Houder van rechten
See clinicaltrials.gov
Geüploaded op
25 september 2018
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Refractory Multiple Myeloma NCT00912899
Eligibility Refractory Multiple Myeloma NCT00912899
- StudyEvent: Eligibility
Similar models
Eligibility Refractory Multiple Myeloma NCT00912899
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Multiple Myeloma Advanced
Item
advanced multiple myeloma.
boolean
C0026764 (UMLS CUI [1,1])
C0205179 (UMLS CUI [1,2])
C0205179 (UMLS CUI [1,2])
Disease Progression | Status post Prior Therapy Course Quantity | Steroids Quantity | Biological Response Modifiers Quantity | Alkylating Agents Quantity | bortezomib | Velcade
Item
progression after ≥ 2 lines of prior therapy, including at least one steroid, one immunomodulatory agent (imid), one alkylator, and bortezomib (velcade®).
boolean
C0242656 (UMLS CUI [1])
C0231290 (UMLS CUI [2,1])
C1514463 (UMLS CUI [2,2])
C0750729 (UMLS CUI [2,3])
C1265611 (UMLS CUI [2,4])
C0038317 (UMLS CUI [3,1])
C1265611 (UMLS CUI [3,2])
C0005525 (UMLS CUI [4,1])
C1265611 (UMLS CUI [4,2])
C0002073 (UMLS CUI [5,1])
C1265611 (UMLS CUI [5,2])
C1176309 (UMLS CUI [6])
C1174739 (UMLS CUI [7])
C0231290 (UMLS CUI [2,1])
C1514463 (UMLS CUI [2,2])
C0750729 (UMLS CUI [2,3])
C1265611 (UMLS CUI [2,4])
C0038317 (UMLS CUI [3,1])
C1265611 (UMLS CUI [3,2])
C0005525 (UMLS CUI [4,1])
C1265611 (UMLS CUI [4,2])
C0002073 (UMLS CUI [5,1])
C1265611 (UMLS CUI [5,2])
C1176309 (UMLS CUI [6])
C1174739 (UMLS CUI [7])
ECOG performance status
Item
ecog performance status of either 0 or 1.
boolean
C1520224 (UMLS CUI [1])
Prior Chemotherapy | Antimitotic Agents
Item
prior chemotherapy with antimicrotubule agents
boolean
C1514457 (UMLS CUI [1])
C0003379 (UMLS CUI [2])
C0003379 (UMLS CUI [2])
Metastatic malignant neoplasm to brain | Secondary malignant neoplasm of spinal cord
Item
metastasis involving the brain or spinal cord
boolean
C0220650 (UMLS CUI [1])
C0347016 (UMLS CUI [2])
C0347016 (UMLS CUI [2])
Lung disease | Heart Disease
Item
clinically significant lung or heart disease
boolean
C0024115 (UMLS CUI [1])
C0018799 (UMLS CUI [2])
C0018799 (UMLS CUI [2])
Electrocardiogram abnormal
Item
abnormal electrocardiogram
boolean
C0522055 (UMLS CUI [1])
Eligibility Criteria Additional
Item
please note that there are additional inclusion and exclusion criteria. the study center will determine if you meet all of the criteria.
boolean
C1516637 (UMLS CUI [1,1])
C1524062 (UMLS CUI [1,2])
C1524062 (UMLS CUI [1,2])
Study Subject Participation Status | Counseling Research Personnel
Item
site personnel will explain the trial in detail and answer any question you may have if you do qualify for the study. you can then decide whether or not you wish to participate. if you do not qualify for the trial, site personnel will explain the reasons.
boolean
C2348568 (UMLS CUI [1])
C0010210 (UMLS CUI [2,1])
C0035173 (UMLS CUI [2,2])
C0010210 (UMLS CUI [2,1])
C0035173 (UMLS CUI [2,2])